Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome

Blood

Volumn 117, Issue 18, 2011, Pages 4871-4880

  Olk Batz, Christiane ^a,b   Poetsch, Anna R ^c   Nöllke, Peter ^a   Claus, Rainer ^c   Zucknick, Manuela ^c   Sandrock, Inga ^a   Witte, Tania ^c   Strahm, Brigitte ^a   Hasle, Henrik ^d   Zecca, Marco ^e   Starý, Jan ^f,g   Bergstraesser, Eva ^h   De Moerloose, Barbara ⁱ   Trebo, Monika ^j   Van Den Heuvel Eibrink, Marry M ^k,l   Wojcik, Dorota ^m   Locatelli, Franco ⁿ   Plass, Christoph ^c   Niemeyer, Charlotte M ^a   Flotho, Christian ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^f CHARLES UNIVERSITY   (Czech Republic)

^g Czech Pediatric Hematology Working Group (CPH)   (Czech Republic)

^h UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j ST ANNA CHILDREN S HOSPITAL   (Austria)

^k ERASMUS MEDICAL CENTER   (Netherlands)

^l DCOG Dutch Childhood Oncology Group   (Netherlands)

^m WROCLAW MEDICAL UNIVERSITY   (Poland)

ⁿ UNIVERSITY OF PAVIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN 4; CALCITONIN; CALCITONIN A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; RETINOIC ACID RECEPTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CPG ISLAND; DNA METHYLATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 79955968990     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-298968     Document Type: Article

References (40)

1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415-428. (Pubitemid 34587077)
2. Boultwood J, Wainscoat JS. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol. 2007;138(1):3-11. (Pubitemid 46889779)
3. Flotho C, Kratz CP, Niemeyer CM. Targeting RAS signaling pathways in juvenile myelomonocytic leukemia. Curr Drug Targets. 2007;8(6):715-725. (Pubitemid 47603401)
4. Loh ML, Sakai DS, Flotho C, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood. 2009;114(9):1859-1863.
5. Steinemann D, Arning L, Praulich I, et al. Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1. Haematologica. 2010;95(2):320-323.
6. Niemeyer CM, Aricò M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. Blood. 1997;89(10):3534-3543. (Pubitemid 27227076)
7. Hasegawa D, Manabe A, Kubota T, et al. Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia. Br J Haematol. 2005;128(6):805-812. (Pubitemid 40444873)
8. Johan MF, Bowen DT, Frew ME, Goodeve AC, Reilly JT. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 2005;129(1):60-65. (Pubitemid 40524052)
9. Liu YL, Castleberry RP, Emanuel PD. PTEN deficiency is a common defect in juvenile myelomonocytic leukemia. Leuk Res. 2009;33(5):671-677.
10. Batz C, Sandrock I, Niemeyer CM, Flotho C. Methylation of the PTEN gene CpG island is infrequent in juvenile myelomonocytic leukemia. Leuk Res. 2009;33(11):1578-1579.
11. Ehrich M, Nelson MR, Stanssens P, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A. 2005;102(44):15785-15790. (Pubitemid 41552820)
12. Graf E, Schmoor C, Sauerbrei W, Schumacher M. Assessment and comparison of prognostic classification schemes for survival data. Stat Med. 1999;18(17-18):2529-2545. (Pubitemid 29423514)
13. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
14. Pepe MS, Longton G, Pettinger M, Mori M, Fisher LD, Storb R. Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: motivation for and description of new methods. Br J Haematol. 1993;83(4):602-607. (Pubitemid 23117438)
15. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706. (Pubitemid 29126745)
16. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant. 2001;28(11):1001-1011. (Pubitemid 34030645)
17. Ordway JM, Williams K, Curran T. Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1. Oncogene. 2004;23(21):3737-3748. (Pubitemid 38725687)
18. Pruitt K, Ulku AS, Frantz K, et al. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem. 2005;280(24):23363-23370. (Pubitemid 40853250)
19. Chang HC, Cho CY, Hung WC. Silencing of the metastasis suppressor RECK by RAS oncogene is mediated by DNA methyltransferase 3b-induced promoter methylation. Cancer Res. 2006;66(17):8413-8420.
20. Locatelli F, Nöllke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood. 2005;105(1):410-419. (Pubitemid 40053113)
21. Hasle H, Baumann I, Bergsträsser E, et al. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia. 2004;18(12):2008-2014. (Pubitemid 40028428)
22. Flotho C, Valcamonica S, Mach-Pascual S, et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia. 1999;13(1):32-37. (Pubitemid 29043714)
23. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8(4):286-298. (Pubitemid 46439286)
24. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res. 2004;32(3):e38.
25. Castleberry RP, Emanuel PD, Zuckerman KS, et al. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med. 1994;331(25):1680-1684. (Pubitemid 24373620)
26. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390(6659):465-471. (Pubitemid 28013118)
27. Pick M, Azzola L, Mossman A, Stanley EG, Elefanty AG. Differentiation of human embryonic stem cells in serum-free medium reveals distinct roles for bone morphogenetic protein 4, vascular endothelial growth factor, stem cell factor, and fibroblast growth factor 2 in hematopoiesis. Stem Cells. 2007;25(9):2206-2214. (Pubitemid 47480479)
28. Nelkin BD, Przepiorka D, Burke PJ, Thomas ED, Baylin SB. Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia. Blood. 1991;77(11):2431-2434.
29. Fazi F, Zardo G, Gelmetti V, et al. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. Blood. 2007;109(10):4432- 4440. (Pubitemid 46743413)
30. Muccio DD, Brouillette WJ, Breitman TR, et al. Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias. J Med Chem. 1998;41(10):1679-1687. (Pubitemid 28221961)
31. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4(12):988-993.
32. Nagy E, Beck Z, Kiss A, et al. Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase. Eur J Cancer. 2003;39(16):2298-2305. (Pubitemid 37214853)
33. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113(6):1315-1325.
34. Bullinger L, Ehrich M, Döhner K, et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood. 2010;115(3):636-642.
35. Bresolin S, Zecca M, Flotho C, et al. Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia. J Clin Oncol. 2010;28(11):1919-1927.
36. Niemeyer CM, Kang MW, Shin DH, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet. 2010;42(9):794-800.
37. Bergstraesser E, Hasle H, Rogge T, et al. Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria. Pediatr Blood Cancer. 2007;49(5):629-633. (Pubitemid 350194425)
38. Flotho C, Kratz CP, Bergstraesser E, et al. Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood. 2008;111(2):966-967.
39. Furlan I, Batz C, Flotho C, et al. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009;113(12):2867-2868.
40. Locatelli F. Tolerance: pregnancy matters. Blood. 2009;114(11):2208-2209.